Discovery Channel features Cysview® - The Health Heros program features advancements in detection of bladder cancer

The Health Heroes program on Discovery Channel featured a six minute educational segment on advancements in detection of bladder cancer.  The program was broadcast on April 15th. Key opinion leaders in Bladder Cancer will be featured: Dr. Gary Steinberg from University of Chicago, Dr. Ashish Kamat, University of Texas – MD Anderson Cancer Center, Houston, Texas and Dr. Sia Daneshmand, USC Norris Cancer Center, Los Angeles, California. The program will also be available for playback on WebMD, YouTube, Global Health Network and Vimeo after the airing on April 15.  

The program was made with support from Photocure.  

Link to videos:

About Cysview/Hexvix®
Cysview/Hexvix is the first approved drug-device combination procedure for improved detection and management of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. It is the first product in a new diagnostic class known as Photodynamic Diagnostic (PDD) agents. Hexvix is an approved product in Europe and the US.  Photocure markets and sells Hexvix in the Nordic region, and has initiated the commercialization of Cysview directly in the US. Ipsen is commercializing Hexvix in Europe excluding Nordics.

About Health Heroes
Health Heroes is a powerful TV series dedicated to defining and exploring today’s latest medical advances in all areas of health and wellness. Written with both the industry professional and television audience in mind, Health Heroes educates, entertains and enlightens the lives of our viewers. For more information about Health Heroes visit their website

For further information, please contact:

President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

CFO Erik Dahl
Tel: +47 50 55 000, Email:

About Photocure ASA
Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology™ platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Information about Photocure is available at

Photodynamic technology is the application of a photosensitizer followed by exposure to light for activation

HPV: human papillomavirus

Photocure Technology™ is Photocure’s specifically designed photosensitizers combined with the exposure to light for diagnosis and/or treatment of specific conditions.

All trademarks mentioned in this release are protected by law and registered trademarks of Photocure.